Filtering by
- Status: Published
![135647-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2021-05/135647-Thumbnail%20Image.png?versionId=84tYGsW3nx.Nu22UA4gnTgyye36sH2uY&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240530/us-west-2/s3/aws4_request&X-Amz-Date=20240530T153840Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=5fe6a267fd36559ddfe1f0124cf1500a7701ccd22ab2fcfec1695e12db78766e&itok=0TlkZ2uD)
![136699-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2021-05/136699-Thumbnail%20Image.png?versionId=GjI3qklHXyNC60P5PDeT66QeTbLfRXa1&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240614/us-west-2/s3/aws4_request&X-Amz-Date=20240614T144751Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=2ef038cab81c5e72776dc72864d3b8284058e2266bd560b1b108bb0452af6c48&itok=2xPveqje)
![136935-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2021-05/136935-Thumbnail%20Image.png?versionId=aUTdk4C1pX6WU6pL2oGcmKifq.utONV9&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240615/us-west-2/s3/aws4_request&X-Amz-Date=20240615T062707Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=0582479c49cee588a92cd33827975848ece07cd8be233277cdc2019ef70ae3ae&itok=peuQNl6h)
The synergistic effects between Vorinostat and Tamoxifen observed through a phase II study on breast cancer patients resistant to hormone therapy may involve more than the modulation of ER-alpha to reverse Tamoxifen resistance in ERBC cells. RT-qPCR of genes expressed in Tamoxifen resistant cells, trefoil factor 1(TFF1) and v-myc avian myelocytomatosis viral oncogene homolog (MYC), were evaluated along with ESR1 and Diablo as a control. MYC was observed to have increased expression in the treated cells, whereas the other genes had a decrease in their expression levels after the cells were treated for 3 days with Vorinostat IC30 of 1 µM. As for targeting the AR, MCF7 Tamoxifen sensitive and resistant cells were not affected by the AR antagonists to determine an IC50. The cell viability for all MCF7 sub-clones only decreased for high concentrations of 5.56 µM - 50 µM in Bicalutamide and 16.67 µM – 50 µM of MDV1300. Furthermore, hormone depletion of MCF7 G11 Tamoxifen resistant sub-clones did not show a great response to DHT stimulation or the AR antagonists. In the RT-qPCR, the MCF7 G11 cells showed an increase in mRNA expression for ER, AR, and PR after 4 hours of treatment with estradiol. As for the DHT treatment, ER, AR, PR, and PSA had a minimal increase in the fold change, but the fold change in AR was less than in the estradiol treatment. The Mayo Clinic will investigate the possible usage of AR as a biomarker through immunohistochemistry.
![137083-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2021-05/137083-Thumbnail%20Image.png?versionId=wfwp1XiFhndM_l_D6BlxiGxJKd_iCqnH&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240614/us-west-2/s3/aws4_request&X-Amz-Date=20240614T081554Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=7f1c0534365656ec070d32e6350caa77d0b178b9ed443b5a3019f0da3b259dcb&itok=QEGPPz4v)
![137735-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2021-05/137735-Thumbnail%20Image.png?versionId=p0eXeP2d03kcFVsH6Euhiot_ftbbE3Gt&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240614/us-west-2/s3/aws4_request&X-Amz-Date=20240614T171244Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=59292f0c61db9dd0f6fad453682f193d9c2d7b6018f4a2523a3f13fdd50cecc3&itok=v4vqSaHP)
![137273-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2021-05/137273-Thumbnail%20Image.png?versionId=Hu0K4Z1UUNTw5dQPNolgpjvNAy5jiqLb&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240606/us-west-2/s3/aws4_request&X-Amz-Date=20240606T101147Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=cda817c6ebc99ba1eabf93a5773e0c75d207e873997ad0f63b544588498d75ea&itok=E-z8Q_a2)
![137413-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2021-05/137413-Thumbnail%20Image.png?versionId=Wv27ioPs6mvEZNOX9ZI2JpfsM9Rw79oM&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240614/us-west-2/s3/aws4_request&X-Amz-Date=20240614T235936Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=a3efc46a79c9f52d040c6424b20949522e6050bc0b070f8d3e20893160dd5796&itok=6E7e336R)
![137471-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2021-05/137471-Thumbnail%20Image.png?versionId=oBm7GR8SlMoe01GHGkxRpxffqdtTIygj&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240614/us-west-2/s3/aws4_request&X-Amz-Date=20240614T171244Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=4559ab9e0e7893b04a4275e191362932a202d2e816494fdfe5d803f01d33e3d3&itok=8MaqFm5-)
![136571-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2021-05/136571-Thumbnail%20Image.png?versionId=B_bmZ0K8fCXnwNcGlw_rvi7KyKtlyAbo&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240615/us-west-2/s3/aws4_request&X-Amz-Date=20240615T202724Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=5b3949d006bbdf5cf2c62b585b2759b527a29cd9e7b35db738f59734997844c5&itok=t-KZLV2M)
![141463-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2021-06/141463-Thumbnail%20Image.png?versionId=ENeUABe2Oyxa57Ihl_PyS6yF4grzWvE3&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240530/us-west-2/s3/aws4_request&X-Amz-Date=20240530T154456Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=25e0b8adb35752d781eb5d677152ca29b3318012766c800a6e41c2bfe78fafe6&itok=goj-kO6R)
Five immunocompetent C57BL/6-cBrd/cBrd/Cr (albino C57BL/6) mice were injected with GL261-luc2 cells, a cell line sharing characteristics of human glioblastoma multiforme (GBM). The mice were imaged using magnetic resonance (MR) at five separate time points to characterize growth and development of the tumor. After 25 days, the final tumor volumes of the mice varied from 12 mm3 to 62 mm3, even though mice were inoculated from the same tumor cell line under carefully controlled conditions. We generated hypotheses to explore large variances in final tumor size and tested them with our simple reaction-diffusion model in both a 3-dimensional (3D) finite difference method and a 2-dimensional (2D) level set method. The parameters obtained from a best-fit procedure, designed to yield simulated tumors as close as possible to the observed ones, vary by an order of magnitude between the three mice analyzed in detail. These differences may reflect morphological and biological variability in tumor growth, as well as errors in the mathematical model, perhaps from an oversimplification of the tumor dynamics or nonidentifiability of parameters. Our results generate parameters that match other experimental in vitro and in vivo measurements. Additionally, we calculate wave speed, which matches with other rat and human measurements.